Apr 5, 2020 · Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing. Antibody therapeutics are one of the most important classes of drugs. Antibody structures have become an integral part of predicting the behavior of potential therapeutics, either directly or as the basis of modeling.

Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.

Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13 receptor signalling (IL-4R, IL-13R), used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis.

Crystal structure of the fab portion of dupilumab. PDB DOI: https://doi.org/10.2210/pdb6WGB/pdb; Classification: IMMUNE SYSTEM; Organism(s): Homo sapiens; Expression System: Cricetulus griseus; Mutation(s): No ; Deposited: 2020-04-05 Released: 2020-09-16

Oct 20, 2016 · Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. 3 As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and ...

Dupilumab is an IgG4 human monoclonal antibody (mAb) that binds IL-4Ra 54,55. Dupilumab inhibits IL-4R signaling induced by both IL-4 and IL-13, and down-regulates TH2 inflammation in a variety of allergic disorders, including atopic dermatitis, asthma and …

Feb 28, 2024 · Dupilumab is an injectable prescription medication administered subcutaneously to treat severe and refractory forms of atopic dermatitis. The US Food and Drug Administration (FDA) approved the medication in April 2017 to treat moderate-to-severe, resistant, atopic dermatitis unresponsive to conventional therapy, including topical corticosteroids.

Dupilumab D10354 Dupilumab (USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 44 Allergic agents 449 Miscellaneous 4490 Miscellaneous D10354 Dupilumab (USAN/INN); Dupilumab (genetical recombination) (JAN) Drug groups [BR:br08330] Immunological agent DG02019 Interleukin inhibitor D10354 Dupilumab

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). [Br J Dermatol. 2018]

Herein, we review the mechanism of action and pharmacology of dupilumab, and the clinical evidence that led to the regulatory approvals of dupilumab for the treatment of numerous type 2 inflammatory diseases: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.